Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
Competitive Comparison of Ocata Therapeutics's 3-Year Book Growth Rate
For the Biotechnology subindustry, Ocata Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocata Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocata Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Ocata Therapeutics's 3-Year Book Growth Rate falls into.
Ocata Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
Ocata Therapeutics (NAS:OCAT) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Ocata Therapeutics 3-Year Book Growth Rate Related Terms
Thank you for viewing the detailed overview of Ocata Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Ocata Therapeutics (Ocata Therapeutics) Business Description
Ocata Therapeutics Inc was incorporated in Nevada under the name Two Moon Kachinas Corp. on May 18, 2000. The Company is a biotechnology company, engaged in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. It is actively conducting clinical trials for treating dry age-related macular degeneration and Stargardt's macular degeneration, in addition to several clinical and preclinical programs for other ocular therapies. It also has a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. Its intellectual property portfolio includes pluripotent human embryonic stem cell, or hESC; induced pluripotent stem cell, or iPSC, platforms; and other cell therapy research programs. It has developed a human photoreceptor progenitor cell. In the U.S., one of the Company's ongoing clinical trials is a Phase 1/2 study for treating dry AMD patients by injection of RPE cells made in culture from an hESC line. It is also conducting Phase 1/2 studies in both the U.S. and the U.K. for the treatment of SMD patients using the RPE cell injections. The Company is conducting three trials in cooperation with retinal surgeons at the top eye hospitals in the U.S. and the U.K. including: Jules Stein Eye Institute (UCLA), Wills Eye Institute, Bascom Palmer Eye Institute (University of Miami) and Massachusetts Eye and Ear Infirmary. As of March 27, 2014, the Company had 46 issued patents and 178 pending patent applications filed, a substantial portion of which pertain to its active product development programs. The Company competes with Pfizer, Regenerative Patch Technologies and the Riken Center for Developmental Biology (Japan), among others. The Company's research and development activities are subject to regulation for safety and efficacy by numerous governmental authorities in the United States and other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OCAT has been successfully added to your